Search Medical Condition
Please enter condition
Please choose location

Bratislava 37, Slovakia Clinical Trials

A listing of Bratislava 37, Slovakia clinical trials actively recruiting patients volunteers.

RESULTS

Found (84) clinical trials

Study Of Diabetic Nephropathy With Atrasentan

The study objective is to evaluate the effect of atrasentan compared with placebo on time to doubling of serum creatinine or the onset of end stage renal disease (ESRD) in subjects with type 2 diabetes and nephropathy who are treated with the maximum tolerated labeled daily dose (MTLDD) of a ...

Phase

0.0 miles

Learn More »

Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors

OBJECTIVES: - Compare progression-free survival rates of patients with poor prognosis stage II or III non-seminomatous germ cell tumors with an unfavorable decrease of tumor markers after treatment with 1 course of bleomycin, etoposide, and cisplatin followed by subsequent treatment with 3 additional courses of bleomycin, etoposide, and cisplatin OR ...

Phase

0.0 miles

Learn More »

Mucopolysaccharidosis I (MPS I) Registry

The MPS I Registry is an international program; in addition to the central contact information provided under the "Location" heading, patients may contact: - In Asia-Pacific - Vivian Liu, +65-6431-2548, Vivian.liu@genzyme.com - In Europe - +31-35-699-1232, europe@mpsiregistry.com - In Latin America - +617-591-5500, help@mpsiregistry.com - In North America - +617-591-5500, ...

Phase N/A

0.0 miles

Learn More »

Fabry Disease Registry

The Fabry Registry is an international program; in addition to the central contact information provided under the "Location" heading, patients may contact: - In Asia-Pacific - Vivian Liu, +65-6431-2548, Vivian.liu@genzyme.com - In Europe - +31-35-699-1232, europe@FabryRegistry.com - In Latin America - +617-591-5500, help@FabryRegistry.com - In North America - +617-591-5500, help@FabryRegistry.com

Phase N/A

0.0 miles

Learn More »

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients Not on Dialysis in Comparison to Darbepoetin Alfa

This study will consist of three study periods as follows: - Screening Period: from 2 up to 6 weeks - Treatment Period: 104 weeks - Follow-up Period: 4 weeks

Phase

0.0 miles

Learn More »